| Literature DB >> 35250940 |
Katharina A Werner1, Anja Poehlein2, Dominik Schneider2, Khaliel El-Said1, Michael Wöhrmann1, Isabel Linkert1, Tobias Hübner3, Nicolas Brüggemann4, Katharina Prost4, Rolf Daniel2, Elisabeth Grohmann1.
Abstract
In times of climate change, practicing sustainable, climate-resilient, and productive agriculture is of primordial importance. Compost from different resources, now treated as wastes, could be one form of sustainable fertilizer creating a resilience of agriculture to the adverse effects of climate change. However, the safety of the produced compost regarding human pathogens, pharmaceuticals, and related resistance genes must be considered. We have assessed the effect of thermophilic composting of dry toilet contents, green cuttings, and straw, with and without biochar, on fecal indicators, the bacterial community, and antibiotic resistance genes (ARGs). Mature compost samples were analyzed regarding fecal indicator organisms, revealing low levels of Escherichia coli that are in line with German regulations for fertilizers. However, one finding of Salmonella spp. exceeded the threshold value. Cultivation of bacteria from the mature compost resulted in 200 isolates with 36.5% of biosafety level 2 (BSL-2) species. The majority is known as opportunistic pathogens that likewise occur in different environments. A quarter of the isolated BSL-2 strains exhibited multiresistance to different classes of antibiotics. Molecular analysis of total DNA before and after composting revealed changes in bacterial community composition and ARGs. 16S rRNA gene amplicon sequencing showed a decline of the two most abundant phyla Proteobacteria (start: 36-48%, end: 27-30%) and Firmicutes (start: 13-33%, end: 12-16%), whereas the abundance of Chloroflexi, Gemmatimonadetes, and Planctomycetes rose. Groups containing many human pathogens decreased during composting, like Pseudomonadales, Bacilli with Bacillus spp., or Staphylococcaceae and Enterococcaceae. Gene-specific PCR showed a decline in the number of detectable ARGs from 15 before to 8 after composting. The results reveal the importance of sufficiently high temperatures lasting for a sufficiently long period during the thermophilic phase of composting for reducing Salmonella to levels matching the criteria for fertilizers. However, most severe human pathogens that were targeted by isolation conditions were not detected. Cultivation-independent analyses also indicated a decline in bacterial orders comprising many pathogenic bacteria, as well as a decrease in ARGs. In summary, thermophilic composting could be a promising approach for producing hygienically safe organic fertilizer from ecological sanitation.Entities:
Keywords: antibiotic resistance genes; bacterial communities; bacterial isolates; biochar; compost; ecological sanitation; human feces; next-generation sequencing
Year: 2022 PMID: 35250940 PMCID: PMC8895236 DOI: 10.3389/fmicb.2022.824834
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Principal coordinates analysis (PCoA) of the 16S rRNA gene amplicon data depicting the dissimilarity of each individual sample toward all others, with PCo1 (x-axis) explaining 74.1% differences and PCo2 (y-axis) explaining 8.2%, respectively. Each data point represents 1 of the 18 compost samples of the trial [E1, E1-B, E2, and E2-B from start (red), 14 days (green; only E1 and E1-B), and end (blue; triplicates per pile)]. Dots represent the treatments with biochar, triangles the ones without.
FIGURE 2Bacterial community composition as assessed by 16S rRNA gene amplicon sequencing. Phyla are represented as percentage of the total number of sequences per sample. Samples from the start and 14 days composting derive from one mixed sample, respectively. Samples from the mature compost (end) are mean values of biological triplicates.
FIGURE 3Heatmap showing the 30 most abundant classes within the 16S rRNA gene amplicon reads. Means of start, 14 days, and end samples are given for the treatments with and without biochar.
FIGURE 4Relative read abundance of the affiliated classes within the phyla Firmicutes (A) and Proteobacteria (B) as depicted by boxplots.
FIGURE 5Alpha diversity of 16S rRNA gene amplicons for start (red), 14 days (green), and end samples (blue), based on (A) the number of amplicon sequence variants (ASV) and (B) Shannon indices.
Presence (+) and absence (−) of ARGs as assessed by PCR in start, 14 days, and end samples (front, middle, and back replicates of each pile) of composting.
| Antibiotic | Resistance gene | E1 (start) | E1 (14 d) | E1 (front) | E1 (middle) | E1 (back) | E1-B (start) | E1-B (14 d) | E1-B (front) | E1-B (middle) | E1-B (back) | E2 (start) | E2 (front) | E2 (middle) | E2 (back) | E2-B (start) | E2-B (front) | E2-B (middle) | E2-B (back) | Start | 14 d | End | |||
| No biochar | biochar | No biochar | Biochar | No biochar | Biochar | ||||||||||||||||||||
| Chloramphenicol |
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
| Fluoroquinolones |
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
| Gentamicin |
| + | + | + | + | + | + | + | + | − | + | + | + | − | − | − | − | − | − | + | + | + | + | + | + |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| + | + | + | + | − | + | + | + | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | |
| Kanamycin |
| + | + | − | − | − | + | + | − | − | − | + | − | − | − | + | − | − | − | + | + | + | + | − | − |
|
| + | + | − | − | − | + | + | − | − | − | + | − | − | − | + | − | − | − | + | + | + | + | − | − | |
| β-lactams |
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
| Erythromycin |
| + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
|
| + | + | − | − | − | + | + | − | − | − | + | − | − | − | − | − | − | − | + | + | + | + | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
|
| + | + | − | + | + | − | + | + | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | |
| Sulfamethoxazole |
| + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
|
| + | + | + | + | + | + | + | + | − | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | |
| Tetracycline |
| + | + | − | − | − | + | + | − | − | − | + | − | − | + | + | − | − | − | + | + | + | + | + | − |
|
| + | + | − | − | − | + | − | − | − | − | + | − | − | − | + | − | − | − | + | + | + | − | − | − | |
|
| + | + | − | − | − | + | + | − | − | − | − | − | − | − | − | − | − | − | + | + | + | + | − | − | |
|
| + | − | + | + | − | + | + | + | + | − | + | + | + | + | + | + | + | + | + | + | − | + | + | + | |
|
| + | − | − | − | − | + | + | − | − | − | + | − | − | − | + | − | − | − | + | + | − | + | − | − | |
|
| + | + | − | − | − | + | + | − | − | − | − | − | − | − | − | − | − | − | + | + | + | + | − | − | |
| Vancomycin |
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
|
| − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | − | |
E1 and E1-B, first repetition, E2 and E2-B, second repetition, “−B” indicating biochar treatment. The last columns (black frame) show the results from the respective replicates combined by time-point [start, 14 days (no replicates available), end], as well as by treatment (no biochar, biochar). “+” indicates that at least one of the replicates was positive.